

**4717.7860 HEALTH RISK LIMITS TABLE.**

Subpart 1. **Generally.** This table lists the health risk limits derived from methods specified in parts 4717.7830, 4717.7840, and 4717.7850. For each chemical, this table specifies:

- A. the chemical name;
- B. the CAS number;
- C. the year the HRL was adopted;
- D. the volatility classification;
- E. any noncancer HRL;
- F. any cancer HRL;
- G. the RfD and RSC used in the derivation of any noncancer HRL;
- H. the slope factor and any ADAF or  $AF_{lifetime}$  used in the derivation of any cancer HRL;
- I. the intake rate used in the derivation of any noncancer or cancer HRL; and
- J. the health endpoints.

**Subp. 2. Explanation of table in this part.**

- A. "-" symbol means not relevant.
- B. "NA" means not applicable.
- C. "ND" means not derived due to absence or paucity of toxicity information.
- D. "None" means not applicable for inclusion in the health risk index.
- E. The following explanations in subitems (1) to (3) apply where noted:
  - (1) The acute HRL value is less than the calculated HRL. To be protective of acute exposures, the HRL is set equal to the acute HRL value.
  - (2) The short-term HRL value is less than the calculated HRL. To be protective of short-term exposures, the HRL is set equal to the short-term HRL value.
  - (3) The subchronic HRL value is less than the calculated HRL. To be protective of subchronic exposures, the HRL is set equal to the subchronic HRL value.

**Subp. 2a. Acetaminophen.**

CAS number: 103-90-2

Year Adopted: 2015

Volatility: Nonvolatile

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	200	200	200 (2)	200 (2)	NA
<b>RfD (mg/kg-day)</b>	0.25	0.25	(2)	(2)	–
<b>RSC</b>	0.2	0.2	(2)	(2)	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	0.289	0.289	(2)	(2)	–
<b>Endpoints</b>	hepatic (liver) system	hepatic (liver) system	hepatic (liver) system	hepatic (liver) system	–

Subp. 3. **Acetochlor.**

CAS number: 34256-82-1

Year Adopted: 2009

Volatility: Nonvolatile

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	40	40	40 (2)	9	NA
<b>RfD (mg/kg-day)</b>	0.021	0.021	(2)	0.002	–
<b>RSC</b>	0.5	0.5	(2)	0.2	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–

<b>Intake Rate (L/kg-day)</b>	0.289	0.289	(2)	0.043	–
<b>Endpoints</b>	developmental	developmental	developmental	hepatic (liver) system, male reproductive system, nervous system, renal (kidney) system, respiratory system	–

Subp. 3a. **Acetochlor ESA.**

CAS number: 187022-11-3

Year Adopted: 2011

Volatility: Nonvolatile

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	ND	600	600	300	NA
<b>RfD (mg/kg-day)</b>	–	0.37	0.23	0.075	–
<b>RSC</b>	–	0.5	0.2	0.2	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	–	0.289	0.077	0.043	–
<b>Endpoints</b>	–	thyroid (E)	thyroid (E)	thyroid (E)	–

Subp. 3b. **Acetochlor OXA.**

CAS number: 184992-44-4

Year Adopted: 2011

Volatility: Nonvolatile

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	ND	200	200	100	NA
<b>RfD (mg/kg-day)</b>	–	0.12	0.077	0.026	–
<b>RSC</b>	–	0.5	0.2	0.2	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	–	0.289	0.077	0.043	–
<b>Endpoints</b>	–	thyroid (E)	thyroid (E)	thyroid (E)	–

Subp. 3c. **Acetone.**

CAS number: 67-64-1

Year Adopted: 2011

Volatility: Moderate

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	ND	9,000	8,000	4,000	NA
<b>RfD (mg/kg-day)</b>	–	5.0	3.0	0.90	–
<b>RSC</b>	–	0.5	0.2	0.2	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	–	0.289	0.077	0.043	–
<b>Endpoints</b>	–	renal (kidney) system	renal (kidney) system, hematological (blood) system	renal (kidney) system, hematological (blood) system	–

Subp. 3d. **6-Acetyl-1,1,2,4,4,7-hexamethyltetraline (AHTN).**

CAS number: 21145-77-7 or 1506-02-1

Year Adopted: 2013

Volatility: Moderate

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	ND	100	30	20	NA
<b>RfD (mg/kg-day)</b>	–	0.070	0.011	0.0037	–
<b>RSC</b>	–	0.5	0.2	0.2	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	–	0.289	0.077	0.043	–
<b>Endpoints</b>	–	hepatic (liver) system	hepatic (liver) system	hepatic (liver) system	–

Subp. 3e. **Acrylamide.**

CAS number: 79-06-1

Year Adopted: 2015

Volatility: Nonvolatile

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	ND	7	7 (2)	7 (2)	0.2
<b>RfD (mg/kg-day)</b>	–	0.010	(2)	(2)	–
<b>RSC</b>	–	0.2	(2)	(2)	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	0.5
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	10 (ADAF <sub>&lt;2</sub> ) 3 (ADAF <sub>2 to &lt;16</sub> ) 1 (ADAF <sub>16+</sub> )

<b>Intake Rate (L/kg-day)</b>	–	0.289	(2)	(2)	0.137 <sub>(&lt;2)</sub> 0.047 <sub>(2 to &lt;16)</sub> 0.039 <sub>(16+)</sub>
<b>Endpoints</b>	–	developmental, male reproductive system, nervous system	developmental, male reproductive system, nervous system	developmental, male reproductive system, nervous system	cancer

Subp. 4. **Alachlor.**

CAS number: 15972-60-8

Year Adopted: 2009

Volatility: Nonvolatile

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	ND	200	30	5	NA
<b>RfD (mg/kg-day)</b>	–	0.1	0.01	0.001	–
<b>RSC</b>	–	0.5	0.2	0.2	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	–	0.289	0.077	0.043	–
<b>Endpoints</b>	–	renal (kidney) system	hepatic (liver) system, hematological (blood) system	hepatic (liver) system, hematological (blood) system	–

Subp. 5. **Atrazine.**

CAS number: 1912-24-9

Year Adopted: 2009

Volatility: Nonvolatile

MCL-based HRL: 3 µg/L

Subp. 5a. **Bentazon.**

CAS number: 25057-89-0

Year Adopted: 2015

Volatility: Nonvolatile

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	400	60	50	30	NA
<b>RfD (mg/kg-day)</b>	0.22	0.033	0.020	0.0060	–
<b>RSC</b>	0.5	0.5	0.2	0.2	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	0.289	0.289	0.077	0.043	–
<b>Endpoints</b>	developmental, female reproductive system	developmental	hematological (blood) system	thyroid	–

Subp. 6. **Benzene.**

CAS number: 71-43-2

Year Adopted: 2009

Volatility: High

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	10	10	3	3 (3)	2
<b>RfD (mg/kg-day)</b>	0.015	0.014	0.0013	(3)	–
<b>RSC</b>	0.2	0.2	0.2	(3)	–

<b>SF (per mg/kg-day)</b>	–	–	–	–	0.055
<b>ADAF</b>	–	–	–	–	10 (ADAF <sub>&lt;2</sub> ) 3 (ADAF <sub>2 to &lt;16</sub> ) 1 (ADAF <sub>16+</sub> )
<b>Intake Rate (L/kg-day)</b>	0.289	0.289	0.077	(3)	0.137 <sub>(&lt;2)</sub> 0.047 <sub>(2 to &lt;16)</sub> 0.039 <sub>(16+)</sub>
<b>Endpoints</b>	developmental	hematological (blood) system, immune system	hematological (blood) system, immune system	hematological (blood) system, immune system	cancer

Subp. 6a. [Renumbered subp 6f]

Subp. 6b. [Renumbered subp 6g]

Subp. 6c. **Bisphenol A (BPA).**

CAS number: 80-05-7

Year Adopted: 2015

Volatility: Nonvolatile

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	ND	100	20	20 (3)	NA
<b>RfD (mg/kg-day)</b>	–	0.16	0.0065	(3)	–
<b>RSC</b>	–	0.2	0.2	(3)	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–



<b>Intake Rate (L/kg-day)</b>	–	0.289	0.077	(3)	–
<b>Endpoints</b>	–	developmental, female reproductive system (E), hepatic (liver) system, male reproductive system (E), renal (kidney) system, thyroid (E)	hepatic (liver) system, renal (kidney) system	hepatic (liver) system, renal (kidney) system	–

Subp. 6d. **Butyl benzyl phthalate.**

CAS number: 85-68-7

Year Adopted: 2015

Volatility: Low

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	100	100	100 (2)	100 (2)	NA
<b>RfD (mg/kg-day)</b>	0.15	0.15	(2)	(2)	–
<b>RSC</b>	0.2	0.2	(2)	(2)	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	0.289	0.289	(2)	(2)	–
<b>Endpoints</b>	developmental (E)	developmental (E)	developmental (E)	developmental (E)	–

Subp. 6e. **Cadmium.**

CAS number: 7440-43-9

Year Adopted: 2015

Volatility: Nonvolatile

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	5	1	1	0.5	NA
<b>RfD (mg/kg-day)</b>	0.0077	0.0016	0.00044	0.00011	–
<b>RSC</b>	0.2	0.2	0.2	0.2	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	0.289	0.289	0.077	0.043	–
<b>Endpoints</b>	developmental	developmental, nervous system, renal (kidney) system	developmental, skeletal	renal (kidney) system, skeletal	–

Subp. 6f. **Carbamazepine.**

CAS number: 298-46-4

Year Adopted: 2013

Volatility: Nonvolatile

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	40	40	40 (2)	40 (2)	NA
<b>RfD (mg/kg-day)</b>	0.013	0.013	(2)	(2)	–
<b>RSC</b>	0.8	0.8	(2)	(2)	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–

<b>Intake Rate (L/kg-day)</b>	0.289	0.289	(2)	(2)	–
<b>Endpoints</b>	developmental, nervous system	developmental, hematological (blood) system, hepatic (liver) system, immune system, nervous system, male reproductive system (E), female reproductive system (E), thyroid (E)	developmental, hematological (blood) system, hepatic (liver) system, immune system, nervous system, male reproductive system (E), female reproductive system (E), thyroid (E)	developmental, hematological (blood) system, hepatic (liver) system, immune system, nervous system, male reproductive system (E), female reproductive system (E), thyroid (E)	–

Subp. 6g. **Carbon tetrachloride.**

CAS number: 56-23-5

Year Adopted: 2013

Volatility: High

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	100	3	3 (2)	3 (2)	1
<b>RfD (mg/kg-day)</b>	0.18	0.0037	(2)	(2)	–
<b>RSC</b>	0.2	0.2	(2)	(2)	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	0.07
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	10 (ADAF <sub>&lt;2</sub> ) 3 (ADAF <sub>2 to &lt;16</sub> ) 1 (ADAF <sub>16+</sub> )

<b>Intake Rate (L/kg-day)</b>	0.289	0.289	(2)	(2)	0.137 <sub>(&lt;2)</sub> 0.047 <sub>(2 to &lt;16)</sub> 0.039 <sub>(16+)</sub>
<b>Endpoints</b>	developmental, hepatic (liver) system	hepatic (liver) system	hepatic (liver) system	hepatic (liver) system	cancer

Subp. 7. **Chloroform.**

CAS number: 67-66-3

Year Adopted: 2009

Volatility: High

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	ND	30	30 (2)	30 (2)	NA
<b>RfD (mg/kg-day)</b>	–	0.05	(2)	(2)	–
<b>RSC</b>	–	0.2	(2)	(2)	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	–	0.289	(2)	(2)	–
<b>Endpoints</b>	–	developmental, hepatic (liver) system, immune system	developmental, hepatic (liver) system, immune system, male reproductive system	developmental, hepatic (liver) system, immune system, male reproductive system	–

Subp. 8. **Cyanazine.**

CAS number: 21725-46-2

Year Adopted: 2009

Volatility: Nonvolatile

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	2	2	2	1	NA
<b>RfD (mg/kg-day)</b>	0.001	0.001	0.00063	0.00026	–
<b>RSC</b>	0.5	0.5	0.2	0.2	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	0.289	0.289	0.077	0.043	–
<b>Endpoints</b>	developmental	developmental	hepatic (liver) system, renal (kidney) system	None	–

Subp. 8a. [Renumbered subp 8f]

Subp. 8b. [Renumbered subp 8g]

Subp. 8c. [Renumbered subp 8h]

Subp. 8d. [Renumbered subp 8i]

Subp. 8e. **Dibutyl phthalate.**

CAS number: 84-74-2

Year Adopted: 2015

Volatility: Low

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	20	20	20 (2)	20 (2)	NA
<b>RfD (mg/kg-day)</b>	0.023	0.023	(2)	(2)	–

<b>RSC</b>	0.2	0.2	(2)	(2)	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	0.289	0.289	(2)	(2)	–
<b>Endpoints</b>	developmental (E)	developmental (E)	developmental (E)	developmental (E)	–

Subp. 8f. **Dichlorodifluoromethane.**

CAS number: 75-71-8

Year Adopted: 2011

Volatility: High

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	ND	ND	ND	700	NA
<b>RfD (mg/kg-day)</b>	–	–	–	0.15	–
<b>RSC</b>	–	–	–	0.2	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	–	–	–	0.043	–
<b>Endpoints</b>	–	–	–	None	–

Subp. 8g. **1,2-Dichloroethane.**

CAS number: 107-06-2

Year Adopted: 2013

Volatility: High

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	ND	200	200 (2)	60	1
<b>RfD (mg/kg-day)</b>	–	0.23	(2)	0.012	–
<b>RSC</b>	–	0.2	(2)	0.2	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	0.091
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	10 (ADAF <sub>&lt;2</sub> ) 3 (ADAF <sub>2 to &lt;16</sub> ) 1 (ADAF <sub>16+</sub> )
<b>Intake Rate (L/kg-day)</b>	–	0.289	(2)	0.043	0.137 <sub>(&lt;2)</sub> 0.047 <sub>(2 to &lt;16)</sub> 0.039 <sub>(16+)</sub>
<b>Endpoints</b>	–	hepatic (liver) system	hepatic (liver) system	renal (kidney) system, hepatic (liver) system	cancer

Subp. 8h. **trans-1,2-Dichloroethene.**

CAS number: 156-60-5

Year Adopted: 2013

Volatility: High

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	ND	ND	200	40	NA
<b>RfD (mg/kg-day)</b>	–	–	0.091	0.0091	–
<b>RSC</b>	–	–	0.2	0.2	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–

<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	–	–	0.077	0.043	–
<b>Endpoints</b>	–	–	immune system	immune system	–

Subp. 8i. **1,1-Dichloroethylene.**

CAS number: 75-35-4

Year Adopted: 2011

Volatility: High

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	ND	ND	200	200	NA
<b>RfD (mg/kg-day)</b>	–	–	0.090	0.046	–
<b>RSC</b>	–	–	0.2	0.2	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	–	–	0.077	0.043	–
<b>Endpoints</b>	–	–	hepatic (liver) system	hepatic (liver) system	–

Subp. 9. **cis 1,2-Dichloroethylene.**

CAS number: 156-59-2

Year Adopted: 2009

Volatility: High

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	ND	70	70 (2)	50	NA
<b>RfD (mg/kg-day)</b>	–	0.097	(2)	0.011	–



<b>RSC</b>	–	0.2	(2)	0.2	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	–	0.289	(2)	0.043	–
<b>Endpoints</b>	–	hematological (blood) system	hematological (blood) system	hematological (blood) system	–

Subp. 10. **Dichloromethane.**

CAS number: 75-09-2

Year Adopted: 2009

Volatility: High

MCL-based HRL: 5 µg/L

Subp. 11. **Dieldrin.**

CAS number: 60-57-1

Year Adopted: 2009

Volatility: Nonvolatile

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	0.2	0.2	0.2 (2)	0.2	0.006
<b>RfD (mg/kg-day)</b>	0.0001	0.0001	(2)	0.00005	–
<b>RSC</b>	0.5	0.5	(2)	0.2	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	16
<b>AF<sub>lifetime</sub></b>	–	–	–	–	2.5

<b>Intake Rate (L/kg-day)</b>	0.289	0.289	(2)	0.043	0.043
<b>Endpoints</b>	developmental	developmental, immune system, nervous system	developmental, immune system, nervous system	hepatic (liver) system, nervous system	cancer

Subp. 11a. [Renumbered subp 11d]

Subp. 11b. [Renumbered subp 11f]

Subp. 11c. **Di(2-ethylhexyl) phthalate (DEHP).**

CAS number: 117-81-7

Year Adopted: 2015

Volatility: Nonvolatile

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	20	20	20 (2)	20 (2)	7
<b>RfD (mg/kg-day)</b>	0.029	0.029	(2)	(2)	–
<b>RSC</b>	0.2	0.2	(2)	(2)	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	0.014
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	10 (ADAF <sub>&lt;2</sub> ) 3 (ADAF <sub>2 to &lt;16</sub> ) 1 (ADAF <sub>16+</sub> )
<b>Intake Rate (L/kg-day)</b>	0.289	0.289	(2)	(2)	0.137 <sub>&lt;2</sub> 0.047 <sub>(2 to &lt;16)</sub> 0.039 <sub>(16+)</sub>
<b>Endpoints</b>	developmental (E), male reproductive system (E)	developmental (E), male reproductive system (E)	developmental (E), male reproductive system (E)	developmental (E), male reproductive system (E)	cancer

Subp. 11d. **N,N-Diethyl-meta-toluamide (DEET).**

CAS number: 134-62-3

Year Adopted: 2013

Volatility: Nonvolatile

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	ND	200	200 (2)	200 (2)	NA
<b>RfD (mg/kg-day)</b>	–	0.23	(2)	(2)	–
<b>RSC</b>	–	0.2	(2)	(2)	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	–	0.289	(2)	(2)	–
<b>Endpoints</b>	–	developmental, nervous system	developmental, nervous system	developmental, nervous system	–

Subp. 11e. **Dimethenamid and Dimethenamid-p.**

CAS numbers: 87674-68-8 and 163515-14-8

Year Adopted: 2015

Volatility: Moderate

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	ND	600	600 (2)	300	NA
<b>RfD (mg/kg-day)</b>	–	0.34	(2)	0.060	–
<b>RSC</b>	–	0.5	(2)	0.2	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–

<b>Intake Rate (L/kg-day)</b>	–	0.289	(2)	0.043	–
<b>Endpoints</b>	–	developmental, female reproductive system, hepatic (liver) system, nervous system	developmental, female reproductive system, hepatic (liver) system, nervous system	hepatic (liver) system	–

Subp. 11f. **1,4-Dioxane.**

CAS number: 123-91-1

Year Adopted: 2013

Volatility: Low

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	ND	ND	300	100	1
<b>RfD (mg/kg-day)</b>	–	–	0.12	0.025	–
<b>RSC</b>	–	–	0.2	0.2	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	0.1
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	10 (ADAF <sub>&lt;2</sub> ) 3 (ADAF <sub>2 to &lt;16</sub> ) 1 (ADAF <sub>16+</sub> )
<b>Intake Rate (L/kg-day)</b>	–	–	0.077	0.043	0.137 <sub>(&lt;2)</sub> 0.047 <sub>(2 to &lt;16)</sub> 0.039 <sub>(16+)</sub>
<b>Endpoints</b>	–	–	hepatic (liver) system, renal (kidney) system, respiratory system	hepatic (liver) system, renal (kidney) system, respiratory system	cancer

## Subp. 12. [Repealed, 40 SR 689]

Subp. 12a. **Ethylbenzene.**

CAS number: 100-41-4

Year Adopted: 2011

Volatility: High

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	ND	50	50 (2)	50 (2)	NA
<b>RfD (mg/kg-day)</b>	–	0.075	(2)	(2)	–
<b>RSC</b>	–	0.2	(2)	(2)	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	–	0.289	(2)	(2)	–
<b>Endpoints</b>	–	hepatic (liver) system, renal (kidney) system	hepatic (liver) system, renal (kidney) system	hepatic (liver) system, renal (kidney) system	–

Subp. 12b. **Ethylene glycol.**

CAS number: 107-21-1

Year Adopted: 2011

Volatility: Nonvolatile

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	4,000	4,000	2,000	2,000	NA
<b>RfD (mg/kg-day)</b>	0.76	0.76	0.72	0.50	–
<b>RSC</b>	0.2	0.2	0.2	0.2	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–

<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	0.043	0.043	0.077	0.043	–
<b>Endpoints</b>	developmental	developmental	renal (kidney) system, developmental	renal (kidney) system, developmental	–

Subp. 12c. **Metolachlor and S-Metolachlor.**

CAS number: 51218-45-2; 87392-12-9

Year Adopted: 2011

Volatility: Nonvolatile

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	400	400	300	300 (3)	NA
<b>RfD (mg/kg-day)</b>	0.24	0.24	0.097	(3)	–
<b>RSC</b>	0.5	0.5	0.2	(3)	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	0.289	0.289	0.077	(3)	–
<b>Endpoints</b>	developmental	developmental	none	none	–

Subp. 12d. **Metolachlor ESA.**

CAS number: 171118-09-5

Year Adopted: 2011

Volatility: Nonvolatile

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	ND	ND	4,000	800	NA

<b>RfD (mg/kg-day)</b>	–	–	1.7	0.17	–
<b>RSC</b>	–	–	0.2	0.2	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	–	–	0.077	0.043	–
<b>Endpoints</b>	–	–	hepatic (liver) system	hepatic (liver) system	–

Subp. 12e. **Metolachlor OXA.**

CAS number: 152019-73-3

Year Adopted: 2011

Volatility: Nonvolatile

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	ND	3,000	3,000 (2)	800	NA
<b>RfD (mg/kg-day)</b>	–	1.7	(2)	0.17	–
<b>RSC</b>	–	0.5	(2)	0.2	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	–	0.289	(2)	0.043	–
<b>Endpoints</b>	–	none	none	none	–

Subp. 12f. **Metribuzin.**

CAS number: 21087-64-9

Year Adopted: 2013

Volatility: Low

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	30	10	10 (2)	10 (2)	NA
<b>RfD (mg/kg-day)</b>	0.016	0.006	(2)	(2)	–
<b>RSC</b>	0.5	0.5	(2)	(2)	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	0.289	0.289	(2)	(2)	–
<b>Endpoints</b>	developmental, nervous system	thyroid (E)	thyroid (E)	thyroid (E)	–

Subp. 12g. **Naphthalene.**

CAS number: 91-20-3

Year Adopted: 2013

Volatility: Moderate

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	70	70	70 (2)	70	NA
<b>RfD (mg/kg-day)</b>	0.038	0.038	(2)	0.016	–
<b>RSC</b>	0.5	0.5	(2)	0.2	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	0.289	0.289	(2)	0.043	–
<b>Endpoints</b>	nervous system	nervous system	nervous system	nervous system, spleen	–

Subp. 13. **Nitrate (as N).**



CAS number: 14797-55-8

Year Adopted: 2009

Volatility: Nonvolatile

MCL-based HRL: 10,000 µg/L

Subp. 14. **Pentachlorophenol (PCP).**

CAS number: 87-86-5

Year Adopted: 2015

Volatility: Low

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	7	7	7 (2)	7 (2)	0.3
<b>RfD (mg/kg-day)</b>	0.0040	0.0040	(2)	(2)	–
<b>RSC</b>	0.5	0.5	(2)	(2)	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	0.4
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	10 (ADAF <sub>&lt;2</sub> ) 3 (ADAF <sub>2 to &lt;16</sub> ) 1 (ADAF <sub>16+</sub> )
<b>Intake Rate (L/kg-day)</b>	0.289	0.289	(2)	(2)	0.137 <sub>(&lt;2)</sub> 0.047 <sub>(2 to &lt;16)</sub> 0.039 <sub>(16+)</sub>
<b>Endpoints</b>	developmental, thyroid (E)	developmental (E), thyroid (E)	developmental (E), hepatic (liver) system, immune system, male reproductive system, thyroid (E)	developmental (E), hepatic (liver) system, immune system, male reproductive system, thyroid (E)	cancer

Subp. 14a. **Perfluorobutane sulfonate (PFBS).**

CAS number: 375-73-5

Year Adopted: 2011

Volatility: Nonvolatile

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	ND	ND	9	7	NA
<b>RfD (mg/kg-day)</b>	–	–	0.0042	0.0014	–
<b>RSC</b>	–	–	0.5	0.2	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	–	–	0.245	0.043	–
<b>Endpoints</b>	–	–	hepatic (liver) system, hematological (blood) system, renal (kidney) system	hepatic (liver) system, hematological (blood) system, renal (kidney) system	–

Subp. 14b. **Perfluorobutyrate (PFBA).**

CAS number: 375-22-4

Year Adopted: 2011

Volatility: Nonvolatile

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	ND	7	7 (2)	7 (2)	NA
<b>RfD (mg/kg-day)</b>	–	0.0038	(2)	(2)	–
<b>RSC</b>	–	0.5	(2)	(2)	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–

<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	–	0.289	(2)	(2)	–
<b>Endpoints</b>	–	hepatic (liver) system, thyroid (E)	hepatic (liver) system, thyroid (E)	hepatic (liver) system, thyroid (E)	–

Subp. 15. **Perfluorooctane sulfonate (PFOS) and salts.**

CAS number: 1763-23-1; 29081-56-9; 2795-39-3; 70225-14-8; and 29457-72-5

Year Adopted: 2009

Volatility: Nonvolatile

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	ND	ND	ND	0.3	NA
<b>RfD (mg/kg-day)</b>	–	–	–	0.00008	–
<b>RSC</b>	–	–	–	0.2	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	–	–	–	0.049	–
<b>Endpoints</b>	–	–	–	developmental, hepatic (liver) system, thyroid (E)	–

Subp. 16. **Perfluorooctanoic acid (PFOA) and salts.**

CAS number: 335-67-1; 3825-26-1; 2395-00-8; 335-93-3; and 335-95-5

Year Adopted: 2009

Volatility: Nonvolatile

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	ND	ND	ND	0.3	NA
<b>RfD (mg/kg-day)</b>	–	–	–	0.000077	–
<b>RSC</b>	–	–	–	0.2	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	–	–	–	0.053	–
<b>Endpoints</b>	–	–	–	developmental, hepatic (liver) system, immune system	–

Subp. 17. **Simazine.**

CAS number: 122-34-9

Year Adopted: 2009

Volatility: Nonvolatile

MCL-based HRL: 4 µg/L

Subp. 17a. **Sulfamethazine (includes sodium salt form).**

CAS number: 57-68-1 (1981-58-4)

Year Adopted: 2015

Volatility: Nonvolatile

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	ND	100	100 (2)	100 (2)	NA
<b>RfD (mg/kg-day)</b>	–	0.040	(2)	(2)	–
<b>RSC</b>	–	0.8	(2)	(2)	–

<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	–	0.289	(2)	(2)	–
<b>Endpoints</b>	–	thyroid	thyroid	thyroid	–

Subp. 18. **1,1,2,2-Tetrachloroethylene.**

CAS number: 127-18-4

Year Adopted: 2009

Volatility: High

MCL-based HRL: 5 µg/L

Subp. 18a. **Toluene.**

CAS number: 108-88-3

Year Adopted: 2011

Volatility: High

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	ND	200	200 (2)	200 (2)	NA
<b>RfD (mg/kg-day)</b>	–	0.22	(2)	(2)	–
<b>RSC</b>	–	0.2	(2)	(2)	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	–	0.289	(2)	(2)	–
<b>Endpoints</b>	–	immune system, nervous system	immune system, nervous system	immune system, nervous system	–

Subp. 18b. **1,2,4-Trichlorobenzene.**

CAS number: 120-82-1

Year Adopted: 2013

Volatility: High

	Acute	Short-term	Subchronic	Chronic	Cancer
<b>HRL (<math>\mu\text{g/L}</math>)</b>	ND	100	100 (2)	100	4
<b>RfD (mg/kg-day)</b>	–	0.17	(2)	0.021	–
<b>RSC</b>	–	0.2	(2)	0.2	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	0.029
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	10 (ADAF <sub>&lt;2</sub> ) 3 (ADAF <sub>2 to &lt;16</sub> ) 1 (ADAF <sub>16+</sub> )
<b>Intake Rate (L/kg-day)</b>	–	0.289	(2)	0.043	0.137 <sub>(&lt;2)</sub> 0.047 <sub>(2 to &lt;16)</sub> 0.039 <sub>(16+)</sub>
<b>Endpoints</b>	–	hepatic (liver) system, adrenal (E), hemato- logical (blood) system	hepatic (liver) system, adrenal (E), hemato- logical (blood) system	hepatic (liver) system, adrenal (E), renal (kidney) system	cancer

Subp. 19. **1,1,1-Trichloroethane.**

CAS number: 71-55-6

Year Adopted: 2009

Volatility: High

	Acute	Short-term	Subchronic	Chronic	Cancer
<b>HRL (<math>\mu\text{g/L}</math>)</b>	ND	ND	20,000	9,000	NA

<b>RfD (mg/kg-day)</b>	–	–	7	2	–
<b>RSC</b>	–	–	0.2	0.2	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	–	–	0.077	0.043	–
<b>Endpoints</b>	–	–	hepatic (liver) system, male reproductive system	hepatic (liver) system, male reproductive system	–

Subp. 20. **1,1,2-Trichloroethylene (TCE).**

CAS number: 79-01-6

Year Adopted: 2015

Volatility: High

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	ND	0.4	0.4	0.4 (3)	2
<b>RfD (mg/kg-day)</b>	–	0.00052	0.00017	(3)	–
<b>RSC</b>	–	0.2	0.2	(3)	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	0.05
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	10 (ADAF <sub>2</sub> ) 3 (ADAF <sub>2 to &lt;16</sub> ) 1 (ADAF <sub>16+</sub> )

<b>Intake Rate (L/kg-day)</b>	–	0.289	0.077	(3)	0.137 <sub>(&lt;2)</sub> 0.047 <sub>(2 to &lt;16)</sub> 0.039 <sub>(16+)</sub>
<b>Endpoints</b>	–	developmental, immune system	developmental, immune system	developmental, immune system	cancer

Subp. 21. **2(2,4,5-Trichlorophenoxy)propionic acid (2,4,5-TP or Silvex).**

CAS number: 93-72-1

Year Adopted: 2009

Volatility: Nonvolatile

MCL-based HRL: 50 µg/L

Subp. 21a. **1,2,3-Trichloropropane.**

CAS number: 96-18-4

Year Adopted: 2013

Volatility: Moderate

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	7	7	7 (2)	7 (2)	0.003
<b>RfD (mg/kg-day)</b>	0.0042	0.0042	(2)	(2)	–
<b>RSC</b>	0.5	0.5	(2)	(2)	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	30
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	10 (ADAF <sub>&lt;2</sub> ) 3 (ADAF <sub>2 to &lt;16</sub> ) 1 (ADAF <sub>16+</sub> )
<b>Intake Rate (L/kg-day)</b>	0.289	0.289	(2)	(2)	0.137 <sub>(&lt;2)</sub> 0.047 <sub>(2 to &lt;16)</sub>



					0.039 <sub>(16+)</sub>
<b>Endpoints</b>	develop- mental	develop- mental	develop- mental	develop- mental	cancer

Subp. 22. **1,3,5-Trimethylbenzene.**

CAS number: 108-67-8

Year Adopted: 2009

Volatility: High

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	ND	100	100 (2)	100 (2)	NA
<b>RfD (mg/kg-day)</b>	ND	0.14	(2)	(2)	–
<b>RSC</b>	–	0.2	(2)	(2)	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	–	0.289	(2)	(2)	–
<b>Endpoints</b>	–	hepatic (liver) system	hepatic (liver) system, renal (kidney) system	hepatic (liver) system, renal (kidney) system	–

Subp. 22a. **Tris(2-chloroethyl) phosphate.**

CAS number: 115-96-8

Year Adopted: 2013

Volatility: Low

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	ND	300	200	200 (3)	5
<b>RfD (mg/kg-day)</b>	–	0.15	0.068	(3)	–

<b>RSC</b>	–	0.5	0.2	(3)	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	0.02
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	10 (ADAF <sub>&lt;2</sub> ) 3 (ADAF <sub>2 to &lt;16</sub> ) 1 (ADAF <sub>16+</sub> )
<b>Intake Rate (L/kg-day)</b>	–	0.289	0.077	(3)	0.137 <sub>(&lt;2)</sub> 0.047 <sub>(2 to &lt;16)</sub> 0.039 <sub>(16+)</sub>
<b>Endpoints</b>	–	renal (kidney) system, nervous system, developmental	renal (kidney) system	renal (kidney) system	cancer

Subp. 23. **Vinyl Chloride.**

CAS number: 75-01-4

Year Adopted: 2009

Volatility: High

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	ND	ND	80	10	0.2
<b>RfD (mg/kg-day)</b>	–	–	0.03	0.003	–
<b>RSC</b>	–	–	0.2	0.2	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	1.4
<b>AF<sub>lifetime</sub></b>	–	–	–	–	1

<b>Intake Rate (L/kg-day)</b>	–	–	0.077	0.043	0.043
<b>Endpoints</b>	–	–	hepatic (liver) system	hepatic (liver) system	cancer

Subp. 23a. **Xylenes.**

CAS number: 1330-20-7

Year Adopted: 2011

Volatility: High

	<b>Acute</b>	<b>Short-term</b>	<b>Subchronic</b>	<b>Chronic</b>	<b>Cancer</b>
<b>HRL (µg/L)</b>	800	300	300 (2)	300 (2)	NA
<b>RfD (mg/kg-day)</b>	1.2	0.5	(2)	(2)	–
<b>RSC</b>	0.2	0.2	(2)	(2)	–
<b>SF (per mg/kg-day)</b>	–	–	–	–	–
<b>ADAF or AF<sub>lifetime</sub></b>	–	–	–	–	–
<b>Intake Rate (L/kg-day)</b>	0.289	0.289	(2)	(2)	–
<b>Endpoints</b>	nervous system	nervous system	renal (kidney) system, nervous system	renal (kidney) system, nervous system	–

Subp. 24. **Transition.** The health risk limits established for the specific chemicals in this part supersede the health risk limits for those chemicals in part 4717.7500. For chemicals not included in this part, the health risk limits established in part 4717.7500 remain in place.

**Statutory Authority:** *MS s 103H.201; 144.0751; 144.12*

**History:** *33 SR 1792; 35 SR 1395; 38 SR 397; 40 SR 689*

**Published Electronically:** *January 4, 2016*